Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mark Larkin"'
Autor:
Jacqueline Palace, Kristl G Claeys, Andreas Meisel, Casey Quinn, Srikanth Muppidi, Francesco Saccà, Sonia Berrih-Aknin, Mark Larkin, Jon Beauchamp, Sandra Paci, Glenn Philips, Fatemeh Amini, Femke De Ruyck, Joyce Ramirez
Publikováno v:
BMJ Open, Vol 13, Iss 5 (2023)
Objectives This study aims to explore the impact of myasthenia gravis (MG) — in terms of treatments, side effects, comorbidities, psychological health and work or study— in the real world from a patient perspective.Design and participants This is
Externí odkaz:
https://doaj.org/article/1abfca6660ea4b04b7ca9028a4ffc0d7
Autor:
Jacqueline Palace, Kristl G Claeys, Renato Mantegazza, Andreas Meisel, Casey Quinn, Srikanth Muppidi, Hiroyuki Murai, Francesco Saccà, Sonia Berrih-Aknin, Sarah Dewilde, Mark Larkin, Jon Beauchamp, Sandra Paci, Laura Day, Glenn Philips, Silvia Chiroli, Guillaume Bassez, MF Janssen
Publikováno v:
BMJ Open, Vol 13, Iss 1 (2023)
Objectives Myasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of
Externí odkaz:
https://doaj.org/article/89526dac77d5406291833a31dcc90782
Autor:
Kristl G Claeys, Renato Mantegazza, Hiroyuki Murai, Francesco Saccà, Sonia Berrih-Aknin, Nancy Law, Sarah Dewilde, Mathieu F Janssen, Emma Bagshaw, Hara Kousoulakou, Mark Larkin, Jon Beauchamp, Trevor Leighton, Sandra Paci
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction Myasthenia gravis (MG) is a rare, chronic, autoimmune disease, mediated by immunoglobulin G antibodies, which causes debilitating muscle weakness. As with most rare diseases, there is little patient-reported data with which to understand
Externí odkaz:
https://doaj.org/article/dbd0be896e044f488a9ab146511d3039
Autor:
Sonia Berrih-Aknin, Jacqueline Palace, Andreas Meisel, Kristl G Claeys, Srikanth Muppidi, Francesco Saccà, Fatemeh Amini, Mark Larkin, Casey Quinn, Jon Beauchamp, Glenn Philips, Femke De Ruyck, Joyce Ramirez, Sandra Paci
ObjectivesThis study aims to explore the impact of myasthenia gravis (MG) — in terms of treatments, side effects, comorbidities, psychological health and work or study— in the real world from a patient perspective.Design and participantsThis is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07544258d6400de5b808d6907c07e322
https://lirias.kuleuven.be/handle/20.500.12942/722105
https://lirias.kuleuven.be/handle/20.500.12942/722105
Autor:
Sarah Dewilde, Glenn Philips, Sandra Paci, Jon Beauchamp, Silvia Chiroli, Casey Quinn, Laura Day, Mark Larkin, Jacqueline Palace, Sonia Berrih-Aknin, Kristl G Claeys, Srikanth Muppidi, Renato Mantegazza, Francesco Saccà, Andreas Meisel, Guillaume Bassez, Hiroyuki Murai, MF Janssen
Publikováno v:
BMJ Open, 13(1):e066445. BMJ Publishing Group
ObjectivesMyasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd05deabdf18f6b879b7c6ab63942671
https://lirias.kuleuven.be/handle/20.500.12942/717379
https://lirias.kuleuven.be/handle/20.500.12942/717379
Publikováno v:
The Patient
Background and Objective Transfusion-dependent β-thalassemia (TDT) is a rare genetic disease characterized by a deficiency of functional β-globin, ultimately leading to lifelong dependence on blood transfusions. There is little patient- and caregiv
Autor:
Florian P. Thomas, Mario A. Saporta, Shahram Attarian, Teresa Sevilla, Rafael Sivera, Gian M. Fabrizi, Filippo Genovese, Amy J. Gray, Simon Bull, Daniel Tanesse, Manuel Rego, Allison Moore, Courtney Hollett, Xavier Paoli, Thomas Sénéchal, Laura Day, Chengyu Ouyang, Samuel Llewellyn, Mark Larkin, Youcef Boutalbi
This study aims to explore the impact of Charcot-Marie-Tooth disease type 1A (CMT1A) and its treatment on patients in European (France, Germany, Italy, Spain, and the United Kingdom) and US real-world practice.Adults with CMT1A (n = 937) were recruit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::657098cba68fda8efd89d3d5bea6fbf1
https://hdl.handle.net/11562/1073227
https://hdl.handle.net/11562/1073227
Autor:
Sonia Berrih-Aknin, Emma Bagshaw, Trevor Leighton, Renato Mantegazza, Hara Kousoulakou, Sandra Paci, Mark Larkin, Sarah Dewilde, Hiroyuki Murai, Nancy Law, Mathieu F. Janssen, Kristl G. Claeys, Jon Beauchamp, Francesco Saccà
Publikováno v:
BMJ Open
BMJ Open, BMJ Publishing Group, 2021, 11 (7), pp.e048198. ⟨10.1136/bmjopen-2020-048198⟩
BMJ Open, Vol 11, Iss 7 (2021)
BMJ Open, 11(7):e048198. BMJ Publishing Group
BMJ Open, BMJ Publishing Group, 2021, 11 (7), pp.e048198. ⟨10.1136/bmjopen-2020-048198⟩
BMJ Open, Vol 11, Iss 7 (2021)
BMJ Open, 11(7):e048198. BMJ Publishing Group
International audience; Download PDFPDFNeurologyProtocolPatient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG) Sonia Berrih-Aknin1, Kristl G Claeys2,3, Nancy Law4, Renato Mantegazza5
Autor:
Allison Moore, Manuel Rego, Samuel Llewellyn, Florian P. Thomas, Mark Larkin, Youcef Boutalbi, Xavier Paoli, Shahram Attarian, Gian Maria Fabrizi, Simon Bull, Teresa Sevilla, Rafael Sivera Mascaró, Amy Gray, Courtney Hollett, Filippo Genovese, Mario Saporta, Katia Monteiro, Daniel Tanesse
Background Charcot-Marie-Tooth disease (CMT) is a rare, chronic, progressive motor and sensory neuropathy that affects the peripheral nervous system, leading to progressive, predominantly distal muscle weakness, atrophy, sensory loss and progressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d195cbe08a3e6ec9ef607fb49ff5f0
https://doi.org/10.21203/rs.3.rs-36305/v2
https://doi.org/10.21203/rs.3.rs-36305/v2
Autor:
Amy Gray, Mark Larkin, Gian Maria Fabrizi, Katia Monteiro, Daniel Tanesse, Simon Bull, Teresa Sevilla, Allison Moore, Florian P. Thomas, Filippo Genovese, Youcef Boutalbi, Courtney Hollett, Samuel Llewellyn, Manuel Rego, Rafael Sivera Mascaró, Mario Saporta, Xavier Paoli, Shahram Attarian
Background Charcot-Marie-Tooth disease (CMT) is a rare, chronic, progressive motor and sensory neuropathy that affects the peripheral nervous system, leading to progressive, predominantly distal muscle weakness, atrophy, sensory loss and progressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48469872daa5348843d5a2e001187d4a
https://doi.org/10.21203/rs.3.rs-36305/v1
https://doi.org/10.21203/rs.3.rs-36305/v1